Research and Markets: The Epilepsy Therapeutics Market is forecast to Register Slow Growth Through 2018 - Pipeline Assessment and Market Forecasts to 2018

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4ca98c/epilepsy_therapeut) has announced the addition of GlobalData's new report "Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

GlobalData, the industry analysis specialist, has released its new report, "Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018." The report is an essential source of information and analysis on the global Epilepsy Therapeutics market. The report identifies the key trends shaping and driving the global Epilepsy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Epilepsy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Epilepsy Therapeutics Market is forecast to Register Slow Growth Through 2018

GlobalData estimates the global epilepsy therapeutics market to be worth $2.9 billion in 2010, and is forecast to register slow growth, with a Compound Annual Growth Rate (CAGR) of 3.5% annually to reach $3.8 billion by 2018. Generic erosion of the leading second generation antiepileptic drugs (AEDs) such as Keppra (levetiracetam), Lamictal (lamotrigine), Topamax (topiramate) and so on is the major factor for the slow growth of the epilepsy therapeutics market during the forecast period. The market is forecast to register a decline due to competition from generics which is predicted to increase over the coming years. The increasing market penetration and availability of generics is likely to act as a barrier for future market players.

Key Topics Covered:

• List of Tables and Figures
• Epilepsy Therapeutics - Introduction
• Epilepsy Therapeutics - Market Characterization
• Epilepsy Therapeutics - Competitive Assessment
• Epilepsy Therapeutics - Pipeline Assessment
• Epilepsy Therapeutics - Clinical Trials Mapping
• Strategic Assessment
• Epilepsy Therapeutics - Future Players
• Epilepsy Therapeutics - Licensing and Partnership Deals
• Epilepsy Therapeutics - Appendix

Companies Mentioned:

• UCB S.A.
• Pfizer
• Supernus Pharmaceuticals, Inc.
• Sunovion Pharmaceuticals Inc.
• GlaxoSmithKline plc
• Nobelpharma Co., Ltd.
• H Lundbeck A/S
• Eisai Co., Ltd.
• Kirin Holdings Company, Limited
• Upsher-smith Laboratories, Inc.

For more information visit http://www.researchandmarkets.com/research/4ca98c/epilepsy_therapeut